Gantenerumab Designated Breakthrough Therapy for Alzheimer Disease
The Food and Drug Administration has granted Breakthrough Therapy designation to gantenerumab for the treatment of Alzheimer disease.
Gantenerumab is an investigational immunoglobulin G1 antibody designed to increase the clearance of soluble amyloid beta from the brain by binding to aggregated forms of amyloid beta.
Gantenerumab Designated Breakthrough Therapy for Alzheimer Disease (empr.com)
![Het beste uit je content halen met een kloppend verhaal [10 stappen]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/businesswoman-working-at-creative-office-2023-11-27-05-24-05-utc-1-80x60.jpg)
